BlueWind’s Revi urinary incontinence device demonstrates three-year efficacy
Medtech companies are increasingly investing in neuromodulation to treat UUI, which is estimated to impact 20% of adults worldwide.
Medical Devices
UK DRI announces trial of blood test for Alzheimer’s diagnosis
New study finds stroke associated with poor glycemic control in diabetics
Revealing the human and business cost of clinical trial inefficiencies for Data Managers and CRAs
Citryll doses first subject in Phase IIa trial of monoclonal antibody for RA
AAIC25: Cognito neuromodulation therapy slows decline in Alzheimer’s disease
Abbott’s studies show CGM technology linked to lower heart hospitalisation risk
Glucotrack hits trial success for direct blood measuring CGM
